Symptomatic Uterine Leiomyoma. Leiomyoma of uterus
Conditions
Interventions
Letrozole drug produced by the pharmaceutical company Soha the amount of 2.5mg / d is administered to patients for a period of twelve weeks..
Treatment - Drugs
Letrozole drug produced by the pharmaceutical company Soha the amount of 2.5mg / d is administered to patients for a period of twelve weeks.
Sponsors
Vice Chancellor for Research of Babol University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 42 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Premenopausal women aged 42-18 years with a single Intramural leiomyoma size> 5 cm; Women with uterine myoma> 5cm with other myoma size 2cm; Women with uterine leiomyomas treated with estrogen or progesterone last month; Women with a history of major medical problems or previous medical or surgical treatment for leiomyomas; All women with leiomyoma sizes 2 to 5cm
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Leiomyoma tumors. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: Ultrasound.;Uterine volume. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: ?????????. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum gonadotropin. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: Laboratory.;Serum Estradiol. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: Laboratory.;Menstrual pattern. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: clinical.;Clinical symptoms associated with leiomyoma. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: clinical. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Asieh Khodami
Hospital Ayatollah Rouhani
Outcome results
None listed